NICE indicators. NM02 Diabetes guidance.
Everything NICE has said on assessing and managing trauma in an interactive flowchart
The percentage of patients with diabetes without moderate or severe frailty, on the register, in whom the last blood pressure reading (measured in the
Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.
The percentage of patients with a new diagnosis of hypertension in the preceding 12 months with a FAST score of ≥3 or AUDIT-C score of ≥5 who have...
The percentage of patients aged 80 years or over with peripheral arterial disease in whom the last blood pressure reading (measured in the preceding...
The percentage of patients aged 80 years or over with coronary heart disease in whom the last blood pressure reading (measured in the preceding 12...
The percentage of patients aged 80 years and over with a history of stroke or TIA in whom the last blood pressure reading (measured in the preceding...
1 How do I control my blood pressure? Lifestyle options and choice of medicines Patient decision aid c NICE 2019. All rights reserved. Subject to...
Everything NICE has said on managing type 2 diabetes in adults in an interactive flowchart
We work with an independent Indicator Advisory Committee (IAC) to develop indicators suitable for potential inclusion in the Quality and Outcomes...
This guideline covers the care and management of type 2 diabetes in adults (aged 18 and over). It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Everything NICE has said on managing the physical and mental health of people in prison, and the mental health of people in the criminal justice system
Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer
Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for type 1 diabetes not controlled by insulin therapy alone in adults with a BMI of at
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.
Everything NICE has said on managing hypertension in adults in an interactive flowchart
Everything NICE has said on how community pharmacies can promote health and wellbeing in an interactive flowchart
Everything NICE has said on diagnosing and managing type 1 diabetes in adults in an interactive flowchart
Everything NICE has said on recognising and managing ovarian cancer in an interactive flowchart
NICE apps for android and apple devices. Includes BNF, BNFC and NICE guidance.
Methodology day presentations - 13 June 2019 Principles underlying the development of NICE guidance - Steven Barnes. An introduction to how health
Please complete all the required fields before submitting the form.RWE Navigator feedback form 1. Please tell us about yourself. Which
Patient access schemes and the NICE Patient Access Liaison Unit When assessing new drugs and treatments, NICE looks at the cost of the treatment and...
NICE research projects and partners.
NICE has today (23 August 2019) announced its intention to work with GW Pharma to address the issues highlighted by its independent appraisal committee in its evaluation of cannabidiol for treating 2 types of severe treatment-resistant epilepsy.
Outside interests of the NICE senior management team
Workshops to help voluntary and community sector organisations learn more about NICE's activities
The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care. Who we are
Chief executive has been at the helm of the institute since it was founded in April 1999
Everything NICE has said on changing people's health-related behaviours, including interventions aimed at over 16s, in an interactive flowchart
Feedback from the GP reference panel survey
Designed for developers of medicinal products and other similarly regulated technologies. Receive advice from NICE, the European Medicines Agency...
Designed for those seeking advice in either pharmaceutical or medical technologies. Provides the highest level of detail of all our advice processes.
Designed for developers of medicinal products and other similarly regulated technologies. Allows you to seek joint regulatory advice from the...
Promoting independence through intermediate care - a quick guide for staff delivering intermediate care services.
Book one of our scientific advice team to speak at your event
Find out more about why engaging with us early is important. We will: introduce NICE present NICE Scientific Advice explain how to complete the
Training seminars and workshops for those in the pharmaceutical, medical technology or cell and gene therapy sectors
Advice on improving the quality of economic models
Scientific advice for developers of pharmaceuticals
NICE Evidence Services issues View the latest issues affecting NICE Evidence Services (Healthcare Databases Advanced Search(HDAS), Evidence Search
Our express service is designed for companies who need to receive scientific advice within more challenging timeframes. Within 12 weeks, you'll...
Scientific advice medtech advice
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults
Everything NICE has said on psoriasis in an interactive flowchart
Everything NICE has said on assessing the risk of, preventing and treating osteoporotic fragility fractures in adults in an interactive flowchart
Everything NICE has said on preventing, diagnosing and managing alcohol-related disorders in an interactive flowchart